Abstract
We reported in 1981 that prostaglandin D2 (PGD2) selectively inhibits tumor cell growth (1). It was verified by Dr. Fukushima’s group in 1985 (2) that a metabolite of PGD2, Δ12-PGJ2 (9-deoxy-Δ9,12-13,14- dihydro-PGD2) was the active form of this PG. Recently we have found that PGD2 and PGA1 derivatives (3,4), which are called the anti-tumor PGs, facilitate mineralization in human osteoblasts. Considering that carcinogenesis enhances bone resorption in general, the concept that anti-tumor PGs stimulate mineralization is an attractive one. I will present data on the stimulative effect of these cyclopentenone PGs and their derivatives on mineralization in human osteoblasts, and discuss a possible mechanism.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
